×
About 13,953 results

ALLMedicine™ Hypertrophic Cardiomyopathy Center

Research & Reviews  6,857 results

Variants in NAA15 cause pediatric hypertrophic cardiomyopathy.
https://doi.org/10.1002/ajmg.a.61928
American Journal of Medical Genetics. Part A REFERENCES; Ritter A, Berger JH et. al.

Oct 26th, 2020 - The NatA N-acetyltransferase complex is important for cotranslational protein modification and regulation of multiple cellular processes. The NatA complex includes the core components of NAA10, the catalytic subunit, and NAA15, the auxiliary compo...

New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on ...
https://doi.org/10.1093/eurheartj/ehaa801
European Heart Journal; Galiuto L, Patrono C

Oct 25th, 2020 - New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on the EXPLORER-HCM trial.|2020|Galiuto L,Patrono C,|

The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy wi...
https://doi.org/10.1093/cvr/cvaa282
Cardiovascular Research; Elliott PM

Oct 23rd, 2020 - The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM.|2020|Elliott PM,|

An East Asian-specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489958
Circulation Wu G, Liu L et. al.

Oct 20th, 2020 - As the US federal government pursues immigration reform, changes to the federal public-charge rule have triggered confusion and concerns among patients who are immigrants. Although federal judges temporarily blocked implementation, a decision by t...

Fractal Analysis: Prognostic Value of Left Ventricular Trabecular Complexity Cardiovasc...
https://doi.org/10.1148/radiol.2020202261
Radiology Wang J, Li Y et. al.

Oct 20th, 2020 - Background The prognostic value of myocardial trabecular complexity in patients with hypertrophic cardiomyopathy (HCM) is unknown. Purpose To explore the prognostic value of myocardial trabecular complexity using fractal analysis in participants w...

see more →

Guidelines  13 results

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2733139

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JC...
https://doi.org/10.1253/circj.CJ-66-0122
Circulation Journal : Official Journal of the Japanese Circulation Society;

Feb 4th, 2016 - Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012) - Digest Version .|2016| ,|diagnosis,physiopathology,therapy,

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Tas...
https://doi.org/10.1093/eurheartj/ehu284
European Heart Journal; , Elliott PM et. al.

Aug 31st, 2014 - 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).|2014| ,Elliott PM,Anastasakis A,Borger MA,B...

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:...
https://doi.org/10.1016/j.jtcvs.2011.10.019
The Journal of Thoracic and Cardiovascular Surgery; , et. al.

Nov 18th, 2011 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.|2011| , , , , ,|diag...

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:...
https://doi.org/10.1016/j.jacc.2011.06.011
Journal of the American College of Cardiology; Gersh BJ, Maron BJ et. al.

Nov 14th, 2011 - 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the Ame...

see more →

Clinicaltrials.gov  6,947 results

Variants in NAA15 cause pediatric hypertrophic cardiomyopathy.
https://doi.org/10.1002/ajmg.a.61928
American Journal of Medical Genetics. Part A REFERENCES; Ritter A, Berger JH et. al.

Oct 26th, 2020 - The NatA N-acetyltransferase complex is important for cotranslational protein modification and regulation of multiple cellular processes. The NatA complex includes the core components of NAA10, the catalytic subunit, and NAA15, the auxiliary compo...

New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on ...
https://doi.org/10.1093/eurheartj/ehaa801
European Heart Journal; Galiuto L, Patrono C

Oct 25th, 2020 - New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on the EXPLORER-HCM trial.|2020|Galiuto L,Patrono C,|

The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy wi...
https://doi.org/10.1093/cvr/cvaa282
Cardiovascular Research; Elliott PM

Oct 23rd, 2020 - The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM.|2020|Elliott PM,|

An East Asian-specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489958
Circulation Wu G, Liu L et. al.

Oct 20th, 2020 - As the US federal government pursues immigration reform, changes to the federal public-charge rule have triggered confusion and concerns among patients who are immigrants. Although federal judges temporarily blocked implementation, a decision by t...

Fractal Analysis: Prognostic Value of Left Ventricular Trabecular Complexity Cardiovasc...
https://doi.org/10.1148/radiol.2020202261
Radiology Wang J, Li Y et. al.

Oct 20th, 2020 - Background The prognostic value of myocardial trabecular complexity in patients with hypertrophic cardiomyopathy (HCM) is unknown. Purpose To explore the prognostic value of myocardial trabecular complexity using fractal analysis in participants w...

see more →

News  101 results

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2733139

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Hydrogen for CHD Surgery? Promising Cardiomyopathy Drug; MITRA-HR Trial
https://www.medpagetoday.com/cardiology/prevention/79636

May 6th, 2019 - Patient-reported outcomes have been collected in only 14% of atrial fibrillation studies on Clinicaltrials.gov. (JACC: Clinical Electrophysiology) Novel cardiac myosin modulator mavacamten met its primary endpoint in obstructive hypertrophic cardi...

Apple Watch algorithm brings wearables closer to clinical practice
https://www.mdedge.com/familymedicine/article/196494/arrhythmias-ep/apple-watch-algorithm-brings-wearables-closer-clinical?channel=39313
MDedge Cardiology; Bruce Jancin

Mar 16th, 2019 - NEW ORLEANS – The portability, convenience, and the mobile health care that wearable technology achieve is clearly being described in the Apple Heart Study, Matthew W. Martinez, MD, medical director of the Sports Cardiology and Hypertrophic Cardio.

Physiological versus pathological cardiac remodeling in athletes
https://www.mdedge.com/internalmedicine/article/194369/imaging/physiological-versus-pathological-cardiac-remodeling?channel=39313
Bruce Jancin

Feb 12th, 2019 - SNOWMASS, COLO. – Cardiac MRI is the go-to tiebreaker when uncertainty exists as to whether cardiac remodeling in a competitive athlete is physiological or pathological, according to Matthew W.

Trimetazidine Disappoints in Non-Obstructive Cardiomyopathy
https://www.medpagetoday.com/cardiology/chf/77854

Feb 6th, 2019 - Another fatty acid β-oxidation inhibitor failed to boost exercise capacity or ease symptoms in non-obstructive hypertrophic cardiomyopathy (HCM) in a small placebo-controlled trial. Study participants who were randomized to trimetazidine had a sma...

see more →

Patient Education  35 results see all →